Compare two psoriasis medicines using real-world patient data
Treatments studied
Part of Skin clinical trials.
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with plaque psoriasis by a dermatologist
- You are starting one of these medicines now: deucravacitinib or apremilast
- You are enrolled in the CorEvitas Psoriasis Registry and have signed consent for research use of registry information
- You are not currently in, and don’t plan to join, any interventional (hands-on) clinical drug trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with moderate to severe psoriasis who are starting a new advanced medication for the first time. Researchers will track how well the treatment works early on to understand what helps different patients improve.
This study follows people starting a new advanced psoriasis treatment to see how well it works over 16 weeks. You'll have three office visits with your dermatologist, and researchers will track your skin improvement to help understand which treatments work best for different patients.
This registry collects information from adults with psoriasis to better understand how psoriasis affects people and how treatments are used in real life. It may help future research and improve knowledge about treatment patterns and outcomes.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study looks at how well deucravacitinib works for people with moderate to severe plaque psoriasis in real-life settings in Italy. It follows patients who have already started the treatment to see how they are doing.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.